Recruiting Diffuse Large B-Cell Lymphoma Studies in San Francisco
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs p...
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen recepto...
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable f...
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated cli...
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitam...
About Diffuse Large B-Cell Lymphoma Clinical Trials in San Francisco
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for about 30% of cases. It is an aggressive lymphoma that grows rapidly. Treatment usually involves chemoimmunotherapy, with CAR-T cell therapy for relapsed cases.
There are currently 5 diffuse large b-cell lymphoma clinical trials recruiting participants in San Francisco, CALIFORNIA. These studies are seeking a combined 1,840 participants. Research is being sponsored by Celgene, SWOG Cancer Research Network, Allogene Therapeutics and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Diffuse Large B-Cell Lymphoma Clinical Trials in San Francisco — FAQ
Are there diffuse large b-cell lymphoma clinical trials in San Francisco?
Yes, there are 5 diffuse large b-cell lymphoma clinical trials currently recruiting in San Francisco, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in San Francisco?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.
Are clinical trials in San Francisco free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.
What diffuse large b-cell lymphoma treatments are being tested?
The 5 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for diffuse large b-cell lymphoma.
Data updated March 2, 2026 from ClinicalTrials.gov